Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Telix Pharmaceuticals Ltd. ( (AU:TLX) ).
Telix Pharmaceuticals reported a record financial performance for FY2024 with a 56% increase in total revenue, driven primarily by sales of Illuccix®. The company achieved significant milestones, including expanding its global supply chain and preparing for new product launches in 2025. Telix’s strategic investments and acquisitions have positioned it for substantial growth in FY2025, with projected revenue guidance of up to $1.23 billion. The company’s focus on precision medicine, late-stage therapeutic development, and global delivery infrastructure expansion underscores its commitment to enhancing international market presence and patient access.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals and related medical technologies. The company is headquartered in Melbourne, Australia, and operates internationally in the United States, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology through its portfolio of clinical and commercial stage products.
YTD Price Performance: 22.55%
Average Trading Volume: 4,376
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.81B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.
